Endocrinologist Audio From Hot Topics in NASH: Real-World Practice Implications of NASH Trial Designs

Expert endocrinologist explains how to interpret endpoints used in NASH studies so you can evaluate emerging treatments.
Kenneth Cusi, MD, FACP, FACE
Program Director
Format: Audio (.mp3)
File Size: 44.19 MB
Released: March 29, 2019

Acknowledgements

Provided by the American Gastroenterological Association

American Gastroenterological Association (AGA)
4930 Del Ray Avenue
Bethesda, MD 20814
Phone: (301) 654-2055
Fax: (301) 654-5920
Email: member@gastro.org

Produced in collaboration with
Endocrine Society Logo
Supported by educational grants from
Gilead Sciences, Inc.
Intercept Pharmaceuticals, Inc.

Related Content

Dr. Stefan Zeuzem discusses new viral hepatitis data reported at the 2020 Digital International Liver Congress, in the CCO Infectious Disease podcast

Stefan Zeuzem, MD Released: September 14, 2020

Expert selections of the most important viral hepatitis data from EASL 2020, including HCV elimination and HCV and HBV treatment, provided by CCO

Stefan Zeuzem, MD Released: September 8, 2020

Hear CCO faculty Philip Newsome discuss the agents in late-phase clinical trials and their potential use in treatment of NASH and fibrosis

Philip N. Newsome, PhD, FRCPE Released: February 12, 2020

CCO faculty Dr Juan Frias discusses the agents in late-phase clinical trials and their potential use in treatment of NASH and fibrosis

Juan Pablo Frias, MD, FACE Released: February 5, 2020

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue